Significant Risk vs. Nonsignificant Risk IDE Studies: Does the US Sponsor Rule Change?

The rule that does not bend: 21 CFR 812.18(a) and the US sponsor requirement

Before your team spends a single hour debating whether your investigational device qualifies as significant risk or nonsignificant risk, there is a threshold question that must be settled first: who can legally sponsor the Investigational Device Exemption (IDE) study in the United States? Under 21 CFR 812.18(a), a company incorporated or operating outside the United States cannot itself serve as the sponsor of an FDA IDE study. A US person, meaning an individual or legal entity with a US address, must accept that role. This requirement is absolute. It does not hinge on risk classification, study size, therapeutic area, or device complexity. It applies on day one, and it applies to every IDE study conducted under FDA jurisdiction.

Does the risk determination change who the sponsor must be?

No. The 21 CFR 812.18(a) requirement that a US person serve as sponsor applies identically to significant risk and nonsignificant risk IDE studies. While 21 CFR 812.2(b) establishes different, abbreviated procedural requirements for nonsignificant risk studies, those streamlined obligations do not modify or waive the sponsor identity rules that govern who may hold the sponsorship role in the first place. A non-US device company studying a nonsignificant risk device in US clinical sites still cannot self-sponsor that study. The abbreviated pathway reduces regulatory burden on the study's conduct; it does not create an exception to the foundational requirement that a US person stand as sponsor of record.

What makes a device 'significant risk'?

Under 21 CFR 812.3(m), a significant risk device is defined in part as one that 'presents a potential for serious risk to the health, safety, or welfare of a subject.' The regulation enumerates specific categories, including devices intended as implants, devices used to support or sustain human life, and devices that are substantially important in diagnosing, curing, mitigating, or treating disease or otherwise preventing impairment of human health. If your device falls into any of these categories, the IDE application to FDA is mandatory before study initiation, along with the full suite of sponsor obligations under 21 CFR Part 812.

For devices that do not meet the significant risk threshold, the nonsignificant risk pathway under 21 CFR 812.2(b) permits sponsors to proceed after IRB approval without a formal IDE submission to FDA. That is a meaningful regulatory advantage. But again, it does not touch the question of who the sponsor must be.

The IRB's role in making the risk determination

The Institutional Review Board plays a central role in the risk determination process, and many device companies are surprised to learn that the sponsor does not simply self-declare nonsignificant risk and move forward. Under FDA's IDE regulations and the agency's guidance on significant risk and nonsignificant risk medical device studies, the sponsor proposes a risk classification and presents supporting rationale to the IRB. The IRB then reviews that rationale independently and reaches its own determination. If the IRB disagrees with the sponsor's assessment and concludes the device is significant risk, the sponsor must either submit a full IDE application to FDA or discontinue the study at that site.

This means that the IRB's risk determination is a regulatory checkpoint, not a formality. Sponsors should prepare a clear, well-documented risk analysis, including a description of the device, its intended use, the study population, and the nature of any foreseeable harms. A thorough risk rationale improves the probability that the IRB can efficiently assess and document its own finding. What the IRB determination does not do, under any circumstance, is alter who is permitted to serve as the legal sponsor of the study. Whether the IRB calls the device significant risk or nonsignificant risk, a US person must hold the sponsor role.

Practical implications for non-US device companies

If your company is headquartered outside the United States and you are planning a US feasibility study, pivotal trial, or any other IDE-regulated investigation, your first regulatory action should be to establish a qualified US Sponsor of Record. That entity accepts legal accountability to FDA for the study, manages IDE submissions or IRB coordination under the nonsignificant risk pathway, maintains required records, and interfaces with clinical sites and investigators. Attempting to operate without a proper US sponsor creates regulatory exposure that no risk classification can cure.

• Review ADB's US Sponsor of Record overview to understand the full scope of sponsor responsibilities.
• Work through the US Sponsor Obligations Checklist to assess your current readiness against 21 CFR Part 812 requirements.
• Use the US Sponsor Decision Tool to review your specific situation and identify next steps.

ADB Consulting and CRO Inc. serves as the US Sponsor of Record for international medical device companies conducting FDA-regulated clinical studies in the United States, providing end-to-end regulatory and clinical oversight under 21 CFR Part 812.

Reviewed October 31, 2026 by ADB's regulatory team.

Frequently asked questions

Can a non-US company avoid the US sponsor requirement by running a nonsignificant risk study instead of a significant risk study?

No. The US sponsor requirement under 21 CFR 812.18(a) applies to all IDE-regulated studies regardless of the risk classification. Choosing the nonsignificant risk pathway changes procedural obligations, such as whether a formal IDE application must be submitted to FDA, but it does not change who is permitted to hold the legal sponsorship role. A non-US company must designate a US Sponsor of Record in either scenario.

Who actually makes the nonsignificant risk determination, the sponsor or the IRB?

The sponsor prepares and proposes a risk classification with supporting rationale. The IRB independently reviews that rationale and makes the official determination. If the IRB concludes the device is significant risk, the sponsor must submit a full IDE application to FDA before proceeding. Sponsors should prepare thorough documentation so the IRB can efficiently assess the proposed classification, but the final call belongs to the IRB.

What happens if a non-US company begins a US IDE study without designating a US sponsor?

Proceeding without a US Sponsor of Record is a violation of 21 CFR 812.18(a) and exposes the study, the investigators, and the sponsoring company to regulatory action by FDA. Clinical data collected under a non-compliant sponsorship structure may also face scrutiny during a future 510(k), De Novo, or PMA submission. The appropriate action is to assess your sponsorship structure before study initiation and correct any gaps before engaging clinical sites.

Ready to assess your US sponsor obligations before your study begins? Book a free discovery call with Andre Butler and the ADB Consulting and CRO Inc. regulatory team at adbccro.com. We work with international device companies at every stage, from early feasibility through pivotal trials, and we can help you prepare the right structure for your US clinical program.

Related reading: our US Sponsor of Record service covers this in more depth.